Jing Zhao1, Yonju Ha2, Gregory I Liou3, Graydon B Gonsalvez4, Sylvia B Smith1, Kathryn E Bollinger1. 1. James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, Georgia, United States. 2. James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, Georgia, United States Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States. 3. James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, Georgia, United States Department of Ophthalmology, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States. 4. Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States.
Abstract
PURPOSE: To evaluate the effects of the σ 1 receptor (σR1) agonist, (+)-pentazocine, on lipopolysaccharide (LPS)-induced inflammatory changes in retinal microglia cells. METHODS: Retinal microglia cells were isolated from Sprague-Dawley rat pups. Cells were treated with LPS with or without (+)-pentazocine and with or without the σR1 antagonist BD1063. Morphologic changes were assayed. Cell viability was assessed by using MTT assay. Supernatant levels of tumor necrosis factor α (TNF-α), interleukin 10, (IL-10), monocyte chemoattractant protein-1 (MCP-1), and nitric oxide (NO) were determined. Reactive oxygen species (ROS) formation was assayed, and levels of mitogen-activated protein kinases (MAPKs) were analyzed by using Western blot. RESULTS: The σR1 protein was expressed in retinal microglia. Incubation with LPS and/or (+)-pentazocine did not alter cell viability or σR1 protein levels. Incubation with LPS for 24 hours induced a marked change in microglial morphology and a significant increase in secreted levels of TNF-α, IL-10, MCP-1, and NO. Pretreatment with (+)-pentazocine inhibited the LPS-induced morphologic changes. Release of TNF-α, IL-10, MCP-1, and NO was reduced with (+)-pentazocine. Intracellular ROS formation was suppressed with (+)-pentazocine. Phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) was reduced in the presence of (+)-pentazocine. The σR1 antagonist BD1063 blocked the (+)-pentazocine-mediated inhibition of LPS-induced morphologic changes. In addition, BD1063 treatment blocked (+)-pentazocine-mediated suppression of LPS-induced TNF-α, IL-10, MCP-1, NO, and intracellular ROS release. CONCLUSIONS: Treatment with (+)-pentazocine suppressed inflammatory responses of retinal microglia and inhibited LPS-induced activation of ERK/JNK MAPK. In neurodegenerative disease, (+)-pentazocine may exert neuroprotective effects through manipulation of microglia. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To evaluate the effects of the σ 1 receptor (σR1) agonist, (+)-pentazocine, on lipopolysaccharide (LPS)-induced inflammatory changes in retinal microglia cells. METHODS: Retinal microglia cells were isolated from Sprague-Dawley rat pups. Cells were treated with LPS with or without (+)-pentazocine and with or without the σR1 antagonist BD1063. Morphologic changes were assayed. Cell viability was assessed by using MTT assay. Supernatant levels of tumor necrosis factor α (TNF-α), interleukin 10, (IL-10), monocyte chemoattractant protein-1 (MCP-1), and nitric oxide (NO) were determined. Reactive oxygen species (ROS) formation was assayed, and levels of mitogen-activated protein kinases (MAPKs) were analyzed by using Western blot. RESULTS: The σR1 protein was expressed in retinal microglia. Incubation with LPS and/or (+)-pentazocine did not alter cell viability or σR1 protein levels. Incubation with LPS for 24 hours induced a marked change in microglial morphology and a significant increase in secreted levels of TNF-α, IL-10, MCP-1, and NO. Pretreatment with (+)-pentazocine inhibited the LPS-induced morphologic changes. Release of TNF-α, IL-10, MCP-1, and NO was reduced with (+)-pentazocine. Intracellular ROS formation was suppressed with (+)-pentazocine. Phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) was reduced in the presence of (+)-pentazocine. The σR1 antagonist BD1063 blocked the (+)-pentazocine-mediated inhibition of LPS-induced morphologic changes. In addition, BD1063 treatment blocked (+)-pentazocine-mediated suppression of LPS-induced TNF-α, IL-10, MCP-1, NO, and intracellular ROS release. CONCLUSIONS: Treatment with (+)-pentazocine suppressed inflammatory responses of retinal microglia and inhibited LPS-induced activation of ERK/JNK MAPK. In neurodegenerative disease, (+)-pentazocine may exert neuroprotective effects through manipulation of microglia. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: F Tan; P L Guio-Aguilar; C Downes; M Zhang; L O'Donovan; J K Callaway; P J Crack Journal: Neuropharmacology Date: 2010-06-09 Impact factor: 5.250
Authors: Brett H Mueller; Yong Park; Donald R Daudt; Hai-Ying Ma; Irina Akopova; Dorota L Stankowska; Abbot F Clark; Thomas Yorio Journal: Exp Eye Res Date: 2012-11-23 Impact factor: 3.467
Authors: Karsten Ruscher; Ana R Inácio; Kristian Valind; Arman Rowshan Ravan; Enida Kuric; Tadeusz Wieloch Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240
Authors: A B El-Remessy; Y Tang; G Zhu; S Matragoon; Y Khalifa; E K Liu; J-Y Liu; E Hanson; S Mian; N Fatteh; G I Liou Journal: Mol Vis Date: 2008-12-03 Impact factor: 2.367
Authors: J Y Moon; D H Roh; S Y Yoon; S R Choi; S G Kwon; H S Choi; S Y Kang; H J Han; A J Beitz; S B Oh; J H Lee Journal: Br J Pharmacol Date: 2014-11-24 Impact factor: 8.739
Authors: Lei Zhao; Guojun Chen; Jun Li; Yingmei Fu; Timur A Mavlyutov; Annie Yao; Robert W Nickells; Shaoqin Gong; Lian-Wang Guo Journal: J Control Release Date: 2017-01-04 Impact factor: 9.776
Authors: Li Jiang; Fan Xu; Wenjing He; Lifei Chen; Haibin Zhong; Yu Wu; Siming Zeng; Li Li; Min Li Journal: Inflamm Res Date: 2016-03-08 Impact factor: 4.575
Authors: Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer Journal: Drug Alcohol Depend Date: 2017-08-31 Impact factor: 4.492